-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Guangdong Province is a major province in China's biopharmaceutical industry, and is building the biopharmaceutical industry into a competitive emerging pillar indust.
The data shows that in recent years, the modern biopharmaceutical industry in Guangdong Province has developed rapidly, showing innovative vitali.
In 2021, a total of 97 drugs have been approved by the state, the number reaching a three-year high, and there are 11,509 valid approval numbers for existing dru.
A total of 25 innovative medical devices have been approved; there are 11,083 Class II registration certificates for medical devices, accounting for nearly 15% of the national total; 2,943 licensed cosmetic manufacturers, accounting for 56% of the national total, and 63 million cosmetic registered products, accounting for the national tot.
of 7
Recently, the Guangdong Provincial Drug Administration announced the new achievements of the "triple (key projects, key enterprises, key regions)" innovative services of Guangdong's biopharmaceutical indust.
Up to now, Guangdong has more than 240,000 certified production and operation enterprises of "two products and one machine"; the total production and circulation value of "two products and one machine" has exceeded one trillion yuan, making it a strategic pillar indust.
The meeting also released the third batch of "triple" innovative service lis.
In 2022, the Guangdong Provincial Drug Administration will promote the innovative development of 13 key projects, including 8 innovative drugs, 4 innovative medical devices and 1 cosmetic new produ.
Raw material project; involving Guangzhou, Shenzhen, Foshan, Dongguan, Huizhou, Zhaoqing, Zhanjiang and other places, a total of 13 pharmaceutical, medical equipment and cosmetic manufacturers are listed as key enterpris.
It is worth mentioning that among the key drug projects, there are 5 new drugs, 2 of which are innovative traditional Chinese medicines, and 1 is an innovative drug for the treatment of lympho.
In recent years, with the support of a series of favorable policies for the research and development of innovative traditional Chinese medicines, both the number of applications and the number of approvals have increased significant.
Data show that in 2021, the number of new Chinese medicine drug approvals will reach 12, far exceeding the sum of the number of approvals in recent yea.
In March this year, China's "14th Five-Year Plan for the Development of Traditional Chinese Medicine" mentioned that it is necessary to build a high-level traditional Chinese medicine inheritance protection and scientific and technological innovation system, and to reform and improve the registration management of traditional Chinese medici.
The industry expects that the new regulations will help further stimulate the research and development of new traditional Chinese medicine drugs, and it is expected that innovative traditional Chinese medicine drugs will usher in an explosi.
Guangdong Province actively supports the research and development of new traditional Chinese medicin.
In recent years, many pharmaceutical companies have harvested new traditional Chinese medicin.
For example, at the end of 2021, Yili Pharmaceutical obtained a new type 1 drug for gout, Huzhen Qingfeng Capsules, and in March 2022, the company submitted a clinical application for a new type 1 Chinese medicine drug of Xiaoerxiangru Granul.
Lymphoma is a malignant tumor that seriously threatens the health of the Chinese population, but it is often ignored due to atypical symptoms (such as lymphadenopathy, fever, night sweats, weight loss, e.
The number of 60,000-80,000 people is increasing, and they are getting younger and young.
"Healthy China Action (2019-2030)" proposes that by 2030, the overall 5-year cancer survival rate will increase by 1
At present, lymphoma patients in China are still faced with the pain points of high misdiagnosis rate and low cure ra.
Various efforts are needed to improve the survival period of lymphoma patients and improve the quality of life of patien.
Guangdong Province promotes the development of innovative drug projects for lymphoma, which is expected to accelerate the progress of new dru.
The biopharmaceutical industry is an emerging indust.
At present, Guangdong Province has become an important highland for the development of China's biopharmaceutical industry, with a large industrial scale and obvious agglomeration effe.
With high-quality development, the policy effects will continue to emerge in the futu.
The data shows that in recent years, the modern biopharmaceutical industry in Guangdong Province has developed rapidly, showing innovative vitali.
In 2021, a total of 97 drugs have been approved by the state, the number reaching a three-year high, and there are 11,509 valid approval numbers for existing dru.
A total of 25 innovative medical devices have been approved; there are 11,083 Class II registration certificates for medical devices, accounting for nearly 15% of the national total; 2,943 licensed cosmetic manufacturers, accounting for 56% of the national total, and 63 million cosmetic registered products, accounting for the national tot.
of 7
Recently, the Guangdong Provincial Drug Administration announced the new achievements of the "triple (key projects, key enterprises, key regions)" innovative services of Guangdong's biopharmaceutical indust.
Up to now, Guangdong has more than 240,000 certified production and operation enterprises of "two products and one machine"; the total production and circulation value of "two products and one machine" has exceeded one trillion yuan, making it a strategic pillar indust.
The meeting also released the third batch of "triple" innovative service lis.
In 2022, the Guangdong Provincial Drug Administration will promote the innovative development of 13 key projects, including 8 innovative drugs, 4 innovative medical devices and 1 cosmetic new produ.
Raw material project; involving Guangzhou, Shenzhen, Foshan, Dongguan, Huizhou, Zhaoqing, Zhanjiang and other places, a total of 13 pharmaceutical, medical equipment and cosmetic manufacturers are listed as key enterpris.
It is worth mentioning that among the key drug projects, there are 5 new drugs, 2 of which are innovative traditional Chinese medicines, and 1 is an innovative drug for the treatment of lympho.
In recent years, with the support of a series of favorable policies for the research and development of innovative traditional Chinese medicines, both the number of applications and the number of approvals have increased significant.
Data show that in 2021, the number of new Chinese medicine drug approvals will reach 12, far exceeding the sum of the number of approvals in recent yea.
In March this year, China's "14th Five-Year Plan for the Development of Traditional Chinese Medicine" mentioned that it is necessary to build a high-level traditional Chinese medicine inheritance protection and scientific and technological innovation system, and to reform and improve the registration management of traditional Chinese medici.
The industry expects that the new regulations will help further stimulate the research and development of new traditional Chinese medicine drugs, and it is expected that innovative traditional Chinese medicine drugs will usher in an explosi.
Guangdong Province actively supports the research and development of new traditional Chinese medicin.
In recent years, many pharmaceutical companies have harvested new traditional Chinese medicin.
For example, at the end of 2021, Yili Pharmaceutical obtained a new type 1 drug for gout, Huzhen Qingfeng Capsules, and in March 2022, the company submitted a clinical application for a new type 1 Chinese medicine drug of Xiaoerxiangru Granul.
Lymphoma is a malignant tumor that seriously threatens the health of the Chinese population, but it is often ignored due to atypical symptoms (such as lymphadenopathy, fever, night sweats, weight loss, e.
The number of 60,000-80,000 people is increasing, and they are getting younger and young.
"Healthy China Action (2019-2030)" proposes that by 2030, the overall 5-year cancer survival rate will increase by 1
At present, lymphoma patients in China are still faced with the pain points of high misdiagnosis rate and low cure ra.
Various efforts are needed to improve the survival period of lymphoma patients and improve the quality of life of patien.
Guangdong Province promotes the development of innovative drug projects for lymphoma, which is expected to accelerate the progress of new dru.
The biopharmaceutical industry is an emerging indust.
At present, Guangdong Province has become an important highland for the development of China's biopharmaceutical industry, with a large industrial scale and obvious agglomeration effe.
With high-quality development, the policy effects will continue to emerge in the futu.
